These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36321230)

  • 1. Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and RAF1 Targets.
    Kityania S; Nath R; Nath D; Patra JK; Talukdar AD
    Comb Chem High Throughput Screen; 2023; 26(10):1907-1919. PubMed ID: 36321230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
    Ma D; Wang J; Liu L; Chen M; Wang Z
    BMC Cancer; 2020 Sep; 20(1):936. PubMed ID: 32993568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated System Pharmacology Approaches to Elucidate Multi-Target Mechanism of
    Khalid HR; Aamir M; Tabassum S; Alghamdi YS; Alzamami A; Ashfaq UA
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing Dual Covalent Irreversible Inhibition of EGFR/FGFR4 by Electrophilic-Based Natural Compounds to Overcome Resistance and Enhance Combination Therapeutic Potentials and Management of Hepatocellular Carcinoma (HCC).
    Xue H; Chen P; Jiao J; Zhu X
    Protein J; 2024 Aug; 43(4):793-804. PubMed ID: 38981944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation.
    Dong Z; Huang K; Liao B; Cai H; Dong Y; Huang M; Zhou X; Jia Y; Xu L; Luo Y; Li ZP; Feng ST
    Eur Radiol; 2019 May; 29(5):2272-2282. PubMed ID: 30547202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
    Gnoni A; Licchetta A; Memeo R; Argentiero A; Solimando AG; Longo V; Delcuratolo S; Brunetti O
    Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31766556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
    Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
    Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking and dynamic simulations of
    Sangeetha R; Arockia Jeya Yasmi Prabha E; Lakshmi A; Sangavi P; Langeswaran K
    J Biomol Struct Dyn; 2022; 40(24):13997-14012. PubMed ID: 34738880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma.
    Zhou R; Wu K; Su M; Li R
    Environ Toxicol Pharmacol; 2019 Aug; 70():103200. PubMed ID: 31158732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma.
    Sauzeau V; Beignet J; Vergoten G; Bailly C
    Pharmacol Res; 2022 May; 179():106220. PubMed ID: 35405309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network pharmacological evaluation of strigolactones efficacy as potential inhibitors against therapeutic targets of hepatocellular carcinoma.
    Amod A; Pahal S; Choudhary P; Gupta A; Singh S
    Biotechnol Lett; 2022 Jul; 44(7):879-900. PubMed ID: 35672528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Docking and Dynamics Simulation Analysis of Thymoquinone and Thymol Compounds from Nigella sativa L. that Inhibits P38 Protein: Probable Remedies for Hepatocellular Carcinoma.
    Tabassum H; Ahmad IZ
    Med Chem; 2020; 16(3):350-357. PubMed ID: 31038073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multilevel data integration and molecular docking approach to systematically elucidate the underlying pharmacological mechanisms of Er-Zhi-Wan against hepatocellular carcinoma.
    Zheng S; Pan B
    Aging (Albany NY); 2022 Nov; 14(21):8783-8804. PubMed ID: 36347033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on molecular mechanism of Solanum nigrum in treatment of hepatocarcinoma based on network pharmacology and molecular docking].
    Liu JH; Lyu DY; Zhou HM; Kuang WH; Chen ZX; Zhang SJ
    Zhongguo Zhong Yao Za Zhi; 2020 Jan; 45(1):163-168. PubMed ID: 32237426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
    Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
    Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An advanced network pharmacology study to explore the novel molecular mechanism of Compound Kushen Injection for treating hepatocellular carcinoma by bioinformatics and experimental verification.
    Lu S; Meng Z; Tan Y; Wu C; Huang Z; Huang J; Fu C; Stalin A; Guo S; Liu X; You L; Li X; Zhang J; Zhou W; Zhang X; Wang M; Wu J
    BMC Complement Med Ther; 2022 Mar; 22(1):54. PubMed ID: 35236335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yupingfeng San exhibits anticancer effect in hepatocellular carcinoma cells via the MAPK pathway revealed by HTS
    Pei T; Dai Y; Tan X; Geng A; Li S; Gui Y; Hu C; An J; Yu X; Bao X; Wang D
    J Ethnopharmacol; 2023 Apr; 306():116134. PubMed ID: 36627003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational assessment of chemicals from
    Ugwah-Oguejiofor CJ; Chukwuka EP; Onifade OF; Agu ST; Adegboyega AE; Johnson GI; Ogunsuyi OI; Johnson TO
    J Biomol Struct Dyn; 2023; 41(22):13271-13286. PubMed ID: 36709454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the mechanisms underlying the therapeutic effect of the
    Qing L; Pan B; He Y; Liu Y; Zhao M; Niu B; Gao X
    Aging (Albany NY); 2022 Nov; 14(22):9103-9127. PubMed ID: 36403263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.